Health and Fitness Health and Fitness
Mon, October 25, 2010
[ Mon, Oct 25th 2010 ] - Market Wire
BioCryst to Present at Oppenheimer Healthcare Conference
[ Mon, Oct 25th 2010 ] - Market Wire
Bestuur Alcon kiest nieuwe voorzitter
[ Mon, Oct 25th 2010 ] - Market Wire
AngioDynamics to Participate at the 21st Annual Oppenheimer Healthcare Conference
[ Mon, Oct 25th 2010 ] - Market Wire
Junta de Alcon elige nuevo presidente
[ Mon, Oct 25th 2010 ] - Market Wire
Il Consiglio di amministrazione di Alcon nomina il suo nuovo Presidente
[ Mon, Oct 25th 2010 ] - Market Wire
Conselho da Alcon elege novo presidente
[ Mon, Oct 25th 2010 ] - Market Wire
Alcon-Verwaltungsrat whlt neuen Vorsitzenden
Sun, October 24, 2010
[ Sun, Oct 24th 2010 ] - Market Wire
Gileada?s Cayston® superieur aan Tobramycine inh .. anden durende head-to-head cystic fibrosis studie
[ Sun, Oct 24th 2010 ] - Market Wire
Alcon Board Elects New Chairman
[ Sun, Oct 24th 2010 ] - Market Wire
HERBALIFE LANZA NUEVOS PRODUCTOS INCLUYENDO BATID .. EINA SIN ALERGENOS Y SUPLEMENTO NUTRICIONAL COQ10
Sat, October 23, 2010
[ Sat, Oct 23rd 2010 ] - Market Wire
Dr. Reddya?s Q2 FY11 Financial Results
Fri, October 22, 2010
[ Fri, Oct 22nd 2010 ] - Market Wire
Cayston® von Gilead zeigt in sechsmonatiger Kopf .. Fibrose berlegenheit gegenber Tobramycin-Inhalat
[ Fri, Oct 22nd 2010 ] - Market Wire
Cayston® di Gilead si dimostrato superiore alla .. alazione in uno studio di raffronto diretto della
[ Fri, Oct 22nd 2010 ] - Market Wire
Law Offices of Howard G. Smith Announces Investig .. rs of Clarient, Inc. in Connection with the Propo
[ Fri, Oct 22nd 2010 ] - Market Wire
MannKind Corporation to Hold 2010 Third Quarter F .. ncial Results Conference Call on October 29, 2010
[ Fri, Oct 22nd 2010 ] - Market Wire
Sycamore Entertainment Group Launches New Corporate Website
[ Fri, Oct 22nd 2010 ] - Market Wire
Faruqi & Faruqi, LLP Announces Investigation Related to the Acquisition of Clarient Inc. a" CLRT
[ Fri, Oct 22nd 2010 ] - Market Wire
Clarient, Inc. Shareholder Investigation by Brisc .. Regarding the Buyout by General Electric Company
[ Fri, Oct 22nd 2010 ] - Market Wire
Cardiac Science Shareholder Investigation by Bris .. ing the Merger with Opto Circuits (India) Limited
[ Fri, Oct 22nd 2010 ] - Market Wire
Kendall Law Group Investigates Clarient, Inc. Acquisition for Shareholders
[ Fri, Oct 22nd 2010 ] - Market Wire
Health Net Federal Services Awarded Department of .. ns Affairs CBO Outpatient Recovery Audit Contract
[ Fri, Oct 22nd 2010 ] - Market Wire
Wright Medical Group, Inc. Announces Full Commerc .. f PRO-STIMa" Osteoinductive Bone Graft Substitute
[ Fri, Oct 22nd 2010 ] - Market Wire
St. Jude Medical Board of Directors Authorizes Share Repurchase
[ Fri, Oct 22nd 2010 ] - Market Wire
Biogen Idec en Genentech melden herstructurering anti-CD20 samenwerkingsovereenkomst
[ Fri, Oct 22nd 2010 ] - Market Wire
Biogen Idec y Genentech anuncian modificacin en su acuerdo de colaboracin de anticuerpos anti-CD20
Thu, October 21, 2010
[ Thu, Oct 21st 2010 ] - Market Wire
Biogen Idec et Genentech annoncent la restructura .. collaboration existant sur la?anticorps anti-CD20
[ Thu, Oct 21st 2010 ] - Market Wire
AMAG Pharmaceuticals, Inc. Announces Data Present .. an Society of Nephrology (ASN) Renal Week Meeting
[ Thu, Oct 21st 2010 ] - Market Wire
Biogen Idec e Genentech annunciano la revisione dell'accordo di collaborazione anti CD20
[ Thu, Oct 21st 2010 ] - Market Wire
Kindred Healthcarea?s Third Quarter Conference Call Scheduled for November 2
[ Thu, Oct 21st 2010 ] - Market Wire
Incyte to Present at the Oppenheimer 21st Annual Healthcare Conference

Incyte to Present at the Oppenheimer 21st Annual Healthcare Conference


Published on 2010-10-21 13:26:23 - Market Wire
  Print publication without navigation


WILMINGTON, Del.--([ BUSINESS WIRE ])--Incyte Corporation (Nasdaq:INCY) announced today it will present at the Oppenheimer 21st Annual Healthcare Conference on Wednesday, November 3, 2010 at 2:10 p.m. ET in New York.

The presentation will be webcast live and can be accessed at [ www.incyte.com ] under Investor Relations, Events and Webcasts. A replay of the presentation will be available for 30 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation. Incyte's most advanced compound, INCB18424, is in Phase III development for myelofibrosis and polycythemia vera. For additional information on Incyte, visit the Company's web site at [ www.incyte.com ].

Contributing Sources